Evidence map›Paper›PMID 38353922›Full record

ArticleJournal of endocrinological investigation2024

Successful localisation of recurrent thyroid cancer using preoperative patent blue dye injection.

B O Evranos, N Ince, H Ataş, S B Polat, H Ahsen, N N Imga, A Dirikoc, O Topaloglu, T Tutuncu, R Ersoy and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

B O EvranosFaculty of Medicine, Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Ankara, Turkey. evranosberna@gmail.com.ORCID http://orcid.org/0000-0002-1848-888X
N InceFaculty of Medicine, Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Ankara, Turkey.
H AtaşFaculty of Medicine, Department of Surgery, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey.
S B PolatFaculty of Medicine, Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Ankara, Turkey.
H AhsenDepartment of Pathology, Ankara Bilkent City Hospital, Ankara, Turkey.
N N ImgaFaculty of Medicine, Department of Endocrinology and Metabolism, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey.
A DirikocFaculty of Medicine, Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Ankara, Turkey.
O TopalogluFaculty of Medicine, Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Ankara, Turkey.
T TutuncuFaculty of Medicine, Department of Surgery, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey.
R ErsoyFaculty of Medicine, Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Ankara, Turkey.
B CakirFaculty of Medicine, Department of Endocrinology and Metabolism, Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Ankara, Turkey.
Ankara Yıldırım Beyazıt University · TRBilkent University · TRSağlık Bilimleri Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn the follow-up of patients with thyroid cancer, recurrences are often detected, posing challenges in locating and removing these lesions in a reoperative setting. This study aimed to assess the effectiveness of preoperative ultrasound (US)-guided injection of patent blue (PB) dye into the recurrences to aid in their safe and efficient removal.

methodsIn this retrospective analysis, we reviewed the records of the patients in a tertiary care centre between February 2019 and March 2023 who underwent US-guided PB injection in the endocrinology outpatient clinic before reoperative neck surgery. The duration between the injection of PB and the initiation of surgery was recorded. The complications and effectiveness of the procedure were evaluated using ultrasonographic, laboratory, surgical, and pathologic records.

resultsWe reached 23 consecutive patients with 28 lesions. The recurrences averaged 8.8 mm (4.1-15.6) in size and were successfully stained in all cases. The median time between the PB injection and the incision was 90 (35-210) min. There were no complications related to the dye injection. The blue recurrences were conveniently identified and removed in all cases.

conclusionsA preoperative US-guided injection of PB is a safe, readily available and highly effective technique for localising recurrent tumours, even in small lesions within scarred reoperative neck surgeries.

Indexed as

Neoplasm Recurrence, LocalPreoperative CareRosaniline DyesThyroid NeoplasmsAdultAgedColoring AgentsFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesThyroidectomyUltrasonography, InterventionalColoring AgentsRosaniline Dyessulfan blueBlue dyeLocalisationPatent blueReoperative surgeryThyroid cancer recurrences

Identifiers

PMID38353922
PMCPMC11266229
OpenAlexW4391815853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.